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Antenatal drug consumption: the burden of self medication in a 
developing world setting 
Abstract 
This institutional-based cross sectional study examines the burden of self medication 
during pregnancy in a middle-income country setting and the impact on fetal 
wellbeing. Using a blend of open-ended and indication-oriented questionnaires, 346 
pregnant women at term were interviewed about their pregnancy complaints and drug 
intake. Inferential statistical data analysis was employed with level of significance (α) 
set at 0.05. Excluding routine supplements and vaccinations, 251(72.5%) women used 
medicines out of whom 79(31.5%) had self-medicated. Consuming drugs without 
prescription was associated with increased US Food & Drug Administration (FDA) 
risk category (χ
2 
= 8.375; p= 0.015). There is therefore a need to scale-up efforts 
towards educating women about dangers of self-medication, whilst also introducing 
effective restrictive policies on over-the-counter drug sales. 











































































Since the tragedy of thalidomide
1
, the need for rational prescription and cautious 
consumption of drugs during pregnancy is well understood 
2
. As a guide to 
prescribers, drugs used in pregnancy have been classified according to risk 
categories 
3-5
. Nonetheless, inappropriate drug use by pregnant women in low- and 
middle income countries (LMICs) persists and self-medication is frequent 
6,7
. There is 
a dearth of information as to what propels pregnant women to self-medicate, the 
pattern of drug use, the extent of self medication and its impact on fetal development. 
 
Methods 
Our study was conducted at the department of Obstetrics and Gynaecology, Ekiti 
State University Teaching Hospital (EKSUTH), Ado-Ekiti, Nigeria between April 1 
and July 31, 2014. EKSUTH is a tertiary health facility located in the capital city of 
Ekiti State, southwest Nigeria and serves as the referral centre for high risk 
pregnancies and complicated labour. Its average annual pool of antenatal attendees is 
3,600 and the hospital delivery rate is 2,500 per year.  
Permission for the conduct of the study was sought and obtained from the Ethics 
Committee of EKSUTH. An estimation of sample size was calculated using a 
previous report of 71.3% prevalence of medication use among pregnant women
8
. 
With a 10% allowance for non-response, an acceptable error margin of 0.05, a 
standard normal deviate of 1.96 and 95% level of confidence, it was calculated that 
346 participants would be needed to power the study adequately. All eligible pregnant 
women (gestational ages of 37-42 weeks) booked for antenatal appointments, who 
gave an informed written consent to participate in the survey, were sequentially 
recruited until the required sample size was reached. 
An interviewer-administered, semi-structured questionnaire was used for data 
collection concerning drugs consumed by the women during their pregnancy. The 
questionnaire was developed from previous studies and was specifically 
conceptualized to fit the study setting. It had 3 sections - information on biodata of 
respondents, modified treatment indication-oriented questions (based on 24 common 
pregnancy disorders which included malaria because of its peculiarity to the study 






























































setting) and, sets of open ended questions as recommended by the Collaborative 
Group on Drug Use in Pregnancy 
9,10
. 
The developed questionnaire was pre-tested in the antenatal clinic for content validity 
and clarity prior to commencement of the study. Based on feedback from the pre-test, 
appropriate corrections were made to the questionnaire. Pregnant women used for the 
pre-test were however excluded from participating in the actual study to avoid data 
contamination. Interviewers were resident doctors purposely trained for the study. 
Since all antenatal attendees are routinely on iron and folic acid supplements owing to 
subsisting high prevalence of anaemia in pregnancy in the study region, haematinics 
and regular vaccinations were excluded from the drug consumption survey. 
Drugs used by participants were categorized according to the FDA risk classification 
3
i
. Drugs consumed were also grouped as prescribed by a health practitioner or bought 
over-the-counter (OTC). Information about drug consumption was obtained at 
interview, but additional information was extracted from respective medical files. The 
number of times in which a drug was either purchased based on prescription or for 
self-medication was noted. 
The collected data was entered into computer software, Statistical Package for Social 
Sciences (SPSS) version 17. The data was cleaned and analyzed using both univariate 
and multivariate statistical methods. Frequency tables were generated to reflect the 
socio-demographic characteristics of respondents, the common complaints during 
pregnancy and medicine used by the pregnant women based on FDA classification. 
Chi square (χ
2
) was used to test for association between OTC drug purchase and 
increased FDA risk category. Logistic regression analysis was equally employed to 
identify socio-demographic factor(s) that predicts self-medication through OTC drug 
purchase. The level of significance (α) was set at 0.05. 
Results 
                                                        
i  
FDA Risk category 
 
Description 
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of 
risk in later trimesters) 
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women 
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despite potential risks 
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, 
but potential benefits may warrant use of the drug in pregnant women despite potential risks 
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction 
data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits 
 






























































As presented in Table 1, of the 346 women interviewed, 131 (37.9%) were 
nulliparous. Only 78 (22.5%) had the index pregnancy unplanned. 
Table 2 displays the overall pattern of complaints by study participants; this 
prevalence was 272/346 (78.6%). Fever topped the list, occurring in 179 (51.7%) of 
respondents; next was the complaint of oedema by 69 (19.1%) followed by headache 
in 56 (16.2%). Vaginal discharge was reported among 49 (14.2%) and 30 (8.7%) 
complained of anorexia or vomiting. Whereas none of the participants had epilepsy, 2 
(0.6%) were diabetic and 8 (2.3%) had hypertension in pregnancy. 
Excluding routine haematinics (iron and folic acid supplements) and vaccinations, the 
prevalence of use of medications by respondents was 251/346 (72.5% of the total 
number of respondents, but 92.3% of those who had complaints). Of the medication 
consumed, 172 (68.5%) were based on prescription by health practitioners while 79 
(31.5%) were by OTC purchase.  
Details of drugs consumed according to risk category are shown in Tables 3 & 4. The 
consumption of drugs with increased FDA risk category was significantly greater for 
OTC medications (χ
2 




Our study shows that more than 75% of our respondents had medical and/or 
gynaecological complaints during their pregnancy, the commonest being fever as in 
available local reports
11,12
. Although endemicity of malaria in our region supports the 
recommendation of routine antenatal administration of intermittent preventive therapy 
(IPT) 
13
, it is worrisome that fever is assumed to be due to malaria, often with no 
testing, and OTC medication taken inappropriately. 
Our study noted that four of the 41 different drugs consumed are classified as risk 
Category D. Most of these were purchased OTC. Although the one respondent who 
purchased Tinidazole stated that it was not used during the first trimester, this drug is 
tagged Category X if consumed then. Some of the Category D drugs used by study 
participants are recorded as being responsible for craniofacial abnormalities, 


































































Self-medication by approximately a third of our respondents is quite alarming but not 
surprising in an environment with poor drug sales regulation. In fact, in Nigeria, 
virtually all drugs can be procured without prescription. This situation may not be 
peculiar to Nigeria alone, as a 28.8% prevalence of self-medication during pregnancy 
was reported in South Africa and 52.2% in Ethiopia 
7,16
. 
Our study found that self-medication is associated with increased risk to the fetus. An 
earlier African study came to the same conclusion 7. This suggests a need to tighten 
policy on OTC drugs while at the same time scaling up education of women 
concerning drug safety during pregnancy. 
Without doubt, interview studies are characterized by inherent memory lapses and 
under-reporting; thus under-estimation of drug consumption is likely. Furthermore, 
many respondents were uncertain concerning the exact timing of consumption of 
OTC drugs, obviously important regarding first trimester category X drugs. 
In conclusion, OTC drugs need strict controls and the sale of medication of category 
D and X to pregnant women should carry a legal penalty.  
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Pregnancy planned?  
Yes 268(77.5) 
No 78(22.5) 






























































Table 2: Common complaints during pregnancy 
#















Imminent miscarriage 4(1.2) 
Insomnia 6(1.7) 





Urinary tract infections 11(3.2) 
Vaginal infections 49(14.2) 
Other infections 4(1.2) 
#
















































































A    
B Methyldopa (3:1); Amoxicillin (6:2); 
Ampicillin/cloxacillin (0:2); 
Ampicillin/Clavulanic acid (2:2); Cimetidine 
(1:0); Erythromycin (3:0); Metronidazole (5:1); 
Nevirapine (3:0); vaginal Nystatin (3:0); 
Paracetamol (48:24); Azithromycin (0:1); 
Cefuroxime (1:1); Proguanil (1:0); 
Nitrofurantoin  (1:0); Chlorpheniramine  (4:2); 
Insulin (2:0); Hydroxyprogesterone (1:0) 
120(37.0%) 17(41.5%) 
C Artesunate (30:10); Anusol suppository (1:0); 
Promethazine (4:1); Camoquine (1:0); 
Chloroquine (7:6); Ciprofloxacin (2:0); 
Clotrimazole pessary (6:4); *Cough mixture 
(10:3); +Sulphadoxine/pyrimethamine (76:9); 
Antacid (4:2); Lamivudine (3:0); Zidovudine 
(3:0); Hydrocortisone (1:0); Nifedipine (1:2); 
Quinine (1:1); Tramadol (2:0); Salbutamol 
(1:1); Prednisolone (1:0); Dexamethasone 
(3:0); ±Tinidazole (1:0) 
197(60.8%) 20(48.8%) 
D Bromazepam (2:2); Acetylsalysalic acid (0:1); 
Doxycycline (1:0); Streptomycin (0:1);  
7(2.2%) 4(9.8%) 
X    
Uncertain   - 
*Cough mixture contains chlopheniramine, pseudoephedrine, and dextromethophan 
or guaifenesin. 
+
Sulphadoxine/pyrimethamine risk increase from ‘C’ to ‘D’ when consumed close to 
term. 





































































Table 4: Relationship between over-the-counter (OTC) drug purchase and increased 




Data presented as n(%); total prevalence of OTC purchase: 79/346(22.8%) 




FDA risk category Total Chi 
square 
P value 
B C D 
Yes 36(45.6) 39(49.4) 4(5.1) 79(100) 8.375 0.015* 
No 84(34.3) 
 
158(64.5) 3(1.2) 245(100)   
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